Stopped: The trial prematurely terminated due to the inability to recruit the planned number of participants. The decision to terminate the trial was not based on any safety and/or efficacy concerns.
The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older. Confirmed renal cell carcinoma Received first line treatment
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Progression Free Survival (PFS)
Timeframe: From treatment initiation date until PD, death or end of follow-up period whichever was earlier (maximum follow-up of 47.1 months)
PFS Rate at Month 6
Timeframe: 6 months post treatment initiation date (during maximum follow-up of 47.1 months)
PFS Rate at Month 9
Timeframe: 9 months post treatment initiation date (during maximum follow-up of 47.1 months)
PFS Rate at Month 12
Timeframe: 12 months post treatment initiation date (during maximum follow-up of 47.1 months)
PFS Rate at Month 18
Timeframe: 18 months post treatment initiation date (during maximum follow-up of 47.1 months)